% IMPORTANT: The following is UTF-8 encoded.  This means that in the presence
% of non-ASCII characters, it will not work with BibTeX 0.99 or older.
% Instead, you should use an up-to-date BibTeX implementation like “bibtex8” or
% “biber”.

@ARTICLE{Urban:289319,
      author       = {K. Urban and A. Gkeka and M. Chandra and D. Greiner and S.
                      Pollich and S. Ruf$^*$ and Y. Kelemen and T. Sundermann and
                      M. Pravetoni and C. Baehr and C. E. Stebbins$^*$ and F. N.
                      Papavasiliou$^*$ and J. P. Verdi$^*$},
      title        = {{T}he fentanyl-specific antibody {F}en{A}b024 can shield
                      against carfentanil effects.},
      journal      = {Toxicology letters},
      volume       = {396},
      issn         = {0378-4274},
      address      = {Amsterdam [u.a.]},
      publisher    = {Elsevier Science},
      reportid     = {DKFZ-2024-00714},
      pages        = {1-10},
      year         = {2024},
      note         = {#LA:D150# / Volume 396, 15 May 2024, Pages 1-10},
      abstract     = {The surge in opioid-related deaths, driven predominantly by
                      fentanyl and its synthetic derivatives, has become a
                      critical public health concern, which is particularly
                      evident in the United States. While the situation is less
                      severe in Europe, the European Monitoring Centre for Drugs
                      and Drug Addiction reports a rise in drug overdose deaths,
                      with emerging concerns about the impact of fentanyl-related
                      molecules. Synthetic opioids, initially designed for medical
                      use, have infiltrated illicit markets due to their low
                      production costs and high potency, with carfentanil posing
                      additional threats, including potential chemical
                      weaponization. Existing overdose mitigation heavily relies
                      on naloxone, requiring timely intervention and caregiver
                      presence, while therapeutic prevention strategies face many
                      access challenges. To provide an additional treatment
                      option, we propose the use of a fentanyl-specific monoclonal
                      antibody (mAb), as a non-opioid method of prophylaxis
                      against fentanyl and carfentanil. This mAb shows protection
                      from opioid effects in a pre-clinical murine model. mAbs
                      could emerge as a versatile countermeasure in civilian and
                      biodefense settings, offering a novel approach to combat
                      opioid-associated mortality.},
      keywords     = {Opioid crisis (Other) / antibody-associated protection
                      (Other) / carfentanil (Other) / fentanyl (Other) /
                      monoclonal antibodies (Other) / passive immunization
                      (Other)},
      cin          = {D150 / D160},
      ddc          = {610},
      cid          = {I:(DE-He78)D150-20160331 / I:(DE-He78)D160-20160331},
      pnm          = {314 - Immunologie und Krebs (POF4-314)},
      pid          = {G:(DE-HGF)POF4-314},
      typ          = {PUB:(DE-HGF)16},
      pubmed       = {pmid:38588756},
      doi          = {10.1016/j.toxlet.2024.03.008},
      url          = {https://inrepo02.dkfz.de/record/289319},
}